Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2009-04-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/ard.2008.104802PMID 19357113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment

  2010cited by this paper
• Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA

  2010cited by this paper
• Bone loss in very early inflammatory back pain in undifferentiated spondyloarthropathy: a 1-year observational study

  2010cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cited by this paper
• The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis

  2010cited by this paper
• Inhibition of p38: has the fat lady sung?

  2009cited by this paper
• Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

  2009cited by this paper
• The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

  2009cited by this paper
• Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.

  2009cited by this paper
• Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study

  2009cited by this paper
• ICH Harmonised Tripartite Guideline

  2009cited by this paper
• Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial

  2009cited by this paper
• Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence

  2008cited by this paper
• Pamapimod, a Novel p38 Mitogen-Activated Protein Kinase Inhibitor: Preclinical Analysis of Efficacy and Selectivity

  2008cited by this paper
• Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

  2008cited by this paper
• Differential tissue expression and activation of p38 MAPK alpha, beta, gamma, and delta isoforms in rheumatoid arthritis.

  2006cited by this paper
• Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

  2006cited by this paper
• Differential tissue expression and activation of p38 MAPK α, β, γ, and δ isoforms in rheumatoid arthritis

  2006cited by this paper
• Kinase Inhibitor-Induced Pustules

  2005cited by this paper
• Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis.

  2000cited by this paper
• Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages.

  1999cited by this paper
• p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials.

  1999cited by this paper
• p38 MAPK signalling cascades in inflammatory disease.

  1999cited by this paper
• Differential Expression and Activation of p38 Mitogen-Activated Protein Kinase a, b, g, and d in Inflammatory Cell Lineages

  1999cited by this paper
• Induction of Cyclooxygenase-2 by the Activated MEKK1 → SEK1/MKK4 → p38 Mitogen-activated Protein Kinase Pathway*

  1998cited by this paper
• INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE

  1996cited by this paper
• The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.

  1993cited by this paper
• The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials

  1993cited by this paper
• Revised criteria for the classification of rheumatoid arthritis.

  1990cited by this paper
• The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

  1988cited by this paper

• Developmental drugs for sarcoidosis.

  2024cites this paper
• Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis

  2023cites this paper
• The KINETIC phase 2 randomized controlled trial of oral pamapimod-pioglitazone in non-critically ill COVID-19 inpatients

  2023cites this paper
• Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research

  2022cites this paper
• Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern

  2022cites this paper
• Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update

  2021cites this paper
• Biologika und „small molecules“ bei der rheumatoiden Arthritis

  2020cites this paper
• Impact factor

  2020cites this paper
• Impact Factor

  2019cites this paper
• Demographic Characteristics of Participants in Rheumatoid Arthritis Randomized Clinical Trials

  2019cites this paper
• Impact Factor :

  2018cites this paper
• Recent Therapeutics Policies of Arthritis Rheumatoid (part I)

  2018cites this paper
• Chapter 65 – Novel Intra-cellular Targeting Agents in Rheumatic Disease

  2017cites this paper
• TLRs, future potential therapeutic targets for RA.

  2017influential citation
• 5.13 – Small Molecule Immunosuppressants in Inflammatory Disease

  2017cites this paper
• Update zu Kinasehemmern 2016

  2016cites this paper
• Rheumatoid arthritis: in past, present and future scenario

  2016cites this paper
• Small molecules with anti-inflammatory properties in clinical development.

  2016cites this paper
• Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development

  2016cites this paper
• Statistical analysis of longitudinal randomized clinical trials with missing data : a comparison of approaches

  2015cites this paper
• 64 – Kinase inhibition: A new therapeutic principle in rheumatology

  2015cites this paper
• Advances in the treatment of rheumatoid arthritis

  2014cites this paper
• Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.

  2014cites this paper
• Mitogen-activated Protein Kinase Phosphatases in Inflammation and as Anti-inflammatory Drug Targets

  2014cites this paper
• Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis

  2014cites this paper
• A meta-analysis of the role of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis

  2013cites this paper
• Mitogen-Activated Protein Kinases as Therapeutic Targets for Rheumatoid Arthritis

  2013cites this paper
• Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis

  2013cites this paper
• Current immunotherapy in rheumatoid arthritis.

  2013cites this paper
• Discovery of a Potent Dihydrooxadiazole Series of Non-ATP-Competitive MK2 (MAPKAPK2) Inhibitors.

  2012cites this paper
• Kinase inhibitors: a new class of antirheumatic drugs

  2012cites this paper
• Therapeutic targets in the ASK1-dependent stress signaling pathways

  2012cites this paper
• Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis.

  2012cites this paper
• A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors.

  2012cites this paper
• Kinase inhibitors: a new class of antirheumatic drugs

  2012cites this paper
• Tec Family Kinases in Inflammation and Disease

  2012cites this paper
• Kinase inhibitors: a new class of antirheumatic drugs

  2012cites this paper
• Lack of the T cell-specific alternative p38 activation pathway reduces autoimmunity and inflammation.

  2011cites this paper
• Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors.

  2011cites this paper
• Immune modulation of rheumatoid arthritis.

  2011cites this paper
• New therapies in the management of rheumatoid arthritis

  2011cites this paper
• Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects.

  2011cites this paper
• 3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.

  2011cites this paper
• Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors

  2011cites this paper
• What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?

  2011cites this paper
• New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors.

  2011cites this paper
• Новые аспекты фармакотерапии ревматоидного артрита: фокус на цертолизумаба пэгол

  2011cites this paper
• Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis

  2010cites this paper
• Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate

  2010cites this paper
• Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis

  2010cites this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

  2010cites this paper
• Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.

  2010cites this paper
• Treating rheumatoid arthritis to target: recommendations of an international task force

  2010cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2010cites this paper
• Differential effects of p38MAP kinase inhibitors on the expression of inflammation‐associated genes in primary, interleukin‐1β‐stimulated human chondrocytes

  2010cites this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

  2010cites this paper
• Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment

  2010cites this paper
• The potential and limitations of p38MAPK as a drug target for the treatment of hematological malignancies.

  2010cites this paper
• Functional analysis of zebrafish innate immune responses to inflammatory signals

  2010cites this paper
• Kinase inhibitors: a new approach to rheumatoid arthritis treatment

  2010cites this paper
• Functional pathway pharmacology: chemical tools, pathway knowledge and mechanistic model-based interpretation of experimental data.

  2010cites this paper
• A Proof‐of‐Concept and Drug‐Drug Interaction Study of Pamapimod, a Novel p38 MAP Kinase Inhibitor, With Methotrexate in Patients With Rheumatoid Arthritis

  2010cites this paper
• Does the p38 MAP kinase inhibitor pamapimod have potential for the treatment of rheumatoid arthritis?

  2010influential citation
• Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population

  2009cites this paper
• Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

  2009cites this paper
• Buch, M. H. et al. (2009) Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging

  2009cites this paper
• No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort

  2009cites this paper
• Diagnosing axial spondyloarthropathy. The new Assessment in SpondyloArthritis international Society criteria: MRI entering centre stage

  2009cites this paper
• The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

  2009cites this paper
• The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathy

  2009cites this paper
• Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level

  2009cites this paper
• Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe

  2009cites this paper
• Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

  2009cites this paper
• Rheumatologie 2009

  2009cites this paper
• A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools

  2009cites this paper
• Clinically relevant advances in rheumatoid arthritis therapy

  2009cites this paper
• The p 38 MAPK inhibitors for the treatment of inflammatory diseases and cancer

  2009cites this paper
• Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

  2008cites this paper
• Corrections

  2008cites this paper
• Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence

  2008influential citation
• Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade

  2008cites this paper
• Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

  2008cites this paper
• The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus

  2008cites this paper
• Open Access Rheumatology: Research and Reviews Dovepress New and Emerging Therapies for the Treatment of Rheumatoid Arthritis

  year unknowncites this paper
• Extended Report

  year unknowncites this paper